CRISPR Therapeutics AGNASDAQ:CRSP
- LAST PRICE53.9100
- TODAY'S CHANGE (%)0.7950 (1.4968%)
- Bid / Lots53.5600/ 5
- Ask / Lots53.9000/ 3
- Open / Previous Close53.6000 / 53.1150
- Day Range
- 52 Week Range
- Volume673,463
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRSP |
|---|---|---|
| 09:32 ET | 14515 | 53.3 |
| 09:34 ET | 1454 | 53.23 |
| 09:36 ET | 1814 | 53.3278 |
| 09:38 ET | 5447 | 53.561 |
| 09:39 ET | 1411 | 53.47 |
| 09:41 ET | 1300 | 53.6388 |
| 09:43 ET | 3712 | 53.905 |
| 09:45 ET | 1210 | 53.7 |
| 09:48 ET | 2350 | 53.6346 |
| 09:50 ET | 5495 | 53.605 |
| 09:52 ET | 8417 | 53.76 |
| 09:54 ET | 2764 | 53.43 |
| 09:56 ET | 3339 | 53.4317 |
| 09:57 ET | 3640 | 53.4355 |
| 09:59 ET | 2843 | 53.45 |
| 10:01 ET | 8459 | 54.05 |
| 10:03 ET | 15452 | 53.875 |
| 10:06 ET | 5074 | 54.025 |
| 10:08 ET | 8809 | 54.26 |
| 10:10 ET | 5286 | 54.31 |
| 10:12 ET | 3558 | 54.3 |
| 10:14 ET | 3335 | 54.335 |
| 10:15 ET | 7712 | 54.3 |
| 10:17 ET | 20788 | 54.5245 |
| 10:19 ET | 9075 | 54.58 |
| 10:21 ET | 6438 | 54.605 |
| 10:24 ET | 19884 | 54.58 |
| 10:26 ET | 8070 | 54.615 |
| 10:28 ET | 5069 | 54.435 |
| 10:30 ET | 7568 | 54.4 |
| 10:32 ET | 2372 | 54.47 |
| 10:33 ET | 1771 | 54.4 |
| 10:35 ET | 3531 | 54.46 |
| 10:37 ET | 1815 | 54.36 |
| 10:39 ET | 1884 | 54.37 |
| 10:42 ET | 2530 | 54.3 |
| 10:44 ET | 2533 | 54.23 |
| 10:46 ET | 3436 | 54.11 |
| 10:48 ET | 4157 | 54.18 |
| 10:50 ET | 4327 | 54.2 |
| 10:51 ET | 3958 | 54.2 |
| 10:53 ET | 11282 | 53.94 |
| 10:55 ET | 3715 | 53.8 |
| 10:57 ET | 1695 | 53.7 |
| 11:00 ET | 9550 | 53.72 |
| 11:02 ET | 2476 | 53.84 |
| 11:04 ET | 15876 | 53.88 |
| 11:06 ET | 6249 | 53.88 |
| 11:08 ET | 1700 | 53.8595 |
| 11:09 ET | 2080 | 53.79 |
| 11:11 ET | 4217 | 53.88 |
| 11:13 ET | 3386 | 53.94 |
| 11:15 ET | 7889 | 53.92 |
| 11:18 ET | 6324 | 54.04 |
| 11:20 ET | 1849 | 53.87 |
| 11:22 ET | 1500 | 53.85 |
| 11:24 ET | 1600 | 53.785 |
| 11:26 ET | 1290 | 53.775 |
| 11:27 ET | 1500 | 53.69 |
| 11:29 ET | 909 | 53.68 |
| 11:31 ET | 2494 | 53.7 |
| 11:33 ET | 500 | 53.65 |
| 11:36 ET | 800 | 53.67 |
| 11:38 ET | 869 | 53.69 |
| 11:40 ET | 500 | 53.67 |
| 11:42 ET | 1329 | 53.6899 |
| 11:44 ET | 8184 | 53.7 |
| 11:45 ET | 2835 | 53.86 |
| 11:47 ET | 775 | 53.81 |
| 11:49 ET | 540 | 53.83 |
| 11:51 ET | 2101 | 53.86 |
| 11:54 ET | 900 | 53.855 |
| 11:56 ET | 2636 | 53.86 |
| 11:58 ET | 1551 | 53.81 |
| 12:00 ET | 1913 | 53.81 |
| 12:02 ET | 2700 | 53.88 |
| 12:03 ET | 4975 | 53.87 |
| 12:05 ET | 2905 | 53.86 |
| 12:07 ET | 1732 | 53.83 |
| 12:09 ET | 1409 | 53.98 |
| 12:12 ET | 2151 | 54 |
| 12:14 ET | 1449 | 54 |
| 12:16 ET | 1145 | 54.1 |
| 12:18 ET | 2341 | 53.89 |
| 12:20 ET | 946 | 53.91 |
| 12:21 ET | 1524 | 53.87 |
| 12:23 ET | 8202 | 53.75 |
| 12:25 ET | 800 | 53.73 |
| 12:27 ET | 2343 | 53.75 |
| 12:30 ET | 1060 | 53.755 |
| 12:32 ET | 1400 | 53.8 |
| 12:34 ET | 1400 | 53.775 |
| 12:36 ET | 700 | 53.765 |
| 12:38 ET | 1024 | 53.76 |
| 12:39 ET | 1025 | 53.84 |
| 12:41 ET | 3983 | 53.87 |
| 12:43 ET | 1112 | 53.9 |
| 12:45 ET | 1387 | 53.9 |
| 12:48 ET | 2983 | 53.905 |
| 12:50 ET | 1000 | 53.94 |
| 12:52 ET | 3400 | 54.039 |
| 12:54 ET | 1600 | 54 |
| 12:56 ET | 8210 | 54 |
| 12:57 ET | 10786 | 53.94 |
| 12:59 ET | 82824 | 53.91 |
Jun 28, 2024
DJ Crispr Therapeutics Coverage Assumed by Guggenheim at Neutral, from 8:06AM ET on Friday Jun 28, 2024 by Dow Jones
8:06AM ET on Friday Jun 28, 2024 by Dow Jones
Jun 27, 2024
DJ Crispr Therapeutics Price Target Maintained With a $88.00/Share by Needham, from 5:45AM ET on Thursday Jun 27, 2024 by Dow Jones
5:45AM ET on Thursday Jun 27, 2024 by Dow Jones
Jun 17, 2024
DJ Crispr Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler, from 1:23PM ET on Monday Jun 17, 2024 by Dow Jones
1:23PM ET on Monday Jun 17, 2024 by Dow JonesDJ Crispr Therapeutics Price Target Maintained With a $88.00/Share by Needham, from 5:45AM ET on Monday Jun 17, 2024 by Dow Jones
5:45AM ET on Monday Jun 17, 2024 by Dow Jones
Jun 13, 2024
DJ S&P 500 Futures Up In Premarket Trading; Broadcom, Tesla Lead, from 7:30AM ET on Thursday Jun 13, 2024 by Dow Jones
7:30AM ET on Thursday Jun 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CRISPR Therapeutics AG | 4.5B | -20.0x | --- |
Apellis Pharmaceuticals Inc | 4.2B | -10.2x | --- |
Ultragenyx Pharmaceutical Inc | 3.8B | -5.0x | --- |
Axsome Therapeutics Inc | 3.7B | -12.6x | --- |
Denali Therapeutics Inc | 3.1B | -22.0x | --- |
Amicus Therapeutics Inc | 2.9B | -19.9x | --- |
Company Information
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Contact Information
- Headquarters
- Baarerstrasse 14ZUG, ZUG, Switzerland 6300
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Samarth Kulkarni
- Chief Financial Officer
- Raju Prasad
- Chief Operating Officer
- Julianne Bruno
- General Counsel, Secretary
- James Kasinger
- Chief Medical Officer
- Naimish Patel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5B |
|---|---|
Revenue (TTM) | $271.7M |
Shares Outstanding | 84.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.70 |
EPS | $-2.70 |
Book Value | $23.52 |
P/E Ratio | -20.0x |
Price/Sales (TTM) | 16.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -109.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
